Research Papers:

IKBKE regulates cell proliferation and epithelial–mesenchymal transition of human malignant glioma via the Hippo pathway

Jie Lu, Yi Yang, Gaochao Guo, Yang Liu, Zhimeng Zhang, Shicai Dong, Yang Nan, Zhenyi Zhao, Yue Zhong and Qiang Huang _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:49502-49514. https://doi.org/10.18632/oncotarget.17738

Metrics: PDF 2941 views  |   HTML 2892 views  |   ?  


Jie Lu1,*, Yi Yang1,*, Gaochao Guo1, Yang Liu1, Zhimeng Zhang1, Shicai Dong1, Yang Nan1, Zhenyi Zhao2, Yue Zhong1 and Qiang Huang1

1Department of Neurosurgery, Tianjin Medical University General Hospital, Heping District, Tianjin 300052, China

2Department of Neurosurgery, Tianjin Baodi People's Hospital, Baodi District, Tianjin 301800, China

*These authors contributed equally to this work

Correspondence to:

Qiang Huang, email: [email protected]

Keywords: IKBKE, epithelial–mesenchymal transition (EMT), glioma, Hippo pathway

Received: October 12, 2016     Accepted: April 24, 2017     Published: May 10, 2017


IKBKE is increased in several types of cancers and is associated with tumour malignancy. In this study, we confirmed that IKBKE promoted glioma proliferation, migration and invasion in vitro. Then, we further discovered that IKBKE increased Yes-associated protein 1 (YAP1) and TEA domain family member 2 (TEAD2), two important Hippo pathway downstream factors, to induce an epithelial–mesenchymal transition (EMT), thus contributing to tumour invasion and metastasis. We also testified that YAP1 and TEAD2 promoted epithelial–mesenchymal transition (EMT) in malignant glioma. Furthermore, we constructed nude mouse subcutaneous and intracranial models to verify that IKBKE could attenuate U87-MG tumourigenicity in vivo. Collectively, our results suggest that IKBKE plays a pivotal role in regulating cell proliferation, invasion and epithelial–mesenchymal transition of malignant glioma cells in vitro and in vivo by impacting on the Hippo pathway. Therefore, targeting IKBKE may become a new strategy to treat malignant glioma.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 17738